



US009175162B2

(12) **United States Patent**
Pacetti et al.(10) **Patent No.:** **US 9,175,162 B2**
(45) **Date of Patent:** ***Nov. 3, 2015**(54) **METHODS FOR FORMING STENT COATINGS COMPRISING HYDROPHILIC ADDITIVES**(75) Inventors: **Stephen D. Pacetti**, San Jose, CA (US);
Yiwen Tang, San Jose, CA (US)(73) Assignee: **Advanced Cardiovascular Systems, Inc.**, Santa Clara, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **11/903,011**(22) Filed: **Sep. 19, 2007**(65) **Prior Publication Data**

US 2008/0021008 A1 Jan. 24, 2008

Related U.S. Application Data

(62) Division of application No. 10/431,711, filed on May 8, 2003, now Pat. No. 7,279,174.

(51) **Int. Cl.****C08L 71/02** (2006.01)
C08L 75/04 (2006.01)
C08L 33/08 (2006.01)
C08L 33/10 (2006.01)
C09D 133/10 (2006.01)
C09D 133/08 (2006.01)
C09D 133/12 (2006.01)
A61L 31/16 (2006.01)
A61L 31/10 (2006.01)(52) **U.S. Cl.**CPC **C08L 71/02** (2013.01); **A61L 31/10** (2013.01); **A61L 31/16** (2013.01); **C08L 75/04** (2013.01); **C09D 133/08** (2013.01); **C09D 133/10** (2013.01); **C09D 133/12** (2013.01); **C08L 33/08** (2013.01); **C08L 33/10** (2013.01)(58) **Field of Classification Search**USPC 424/422; 623/1.42
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**590,263 A 9/1897 Henry
2,072,303 A 3/1937 Herrmann et al.
2,386,454 A 10/1945 Frosch et al.
3,178,399 A 4/1965 Lo
3,773,737 A 11/1973 Goodman et al.
3,849,514 A 11/1974 Gray, Jr. et al.
4,226,243 A 10/1980 Shalaby et al.
4,268,650 A * 5/1981 Rose 525/534
4,329,383 A 5/1982 Joh
4,343,931 A 8/1982 Barrows
4,529,792 A 7/1985 Barrows
4,564,013 A 1/1986 Lilienfeld et al.
4,611,051 A 9/1986 Hayes et al.
4,656,242 A 4/1987 Swan et al.4,733,665 A 3/1988 Palmaz
4,752,624 A 6/1988 Kim et al.
4,765,916 A * 8/1988 Ogar et al. 510/513
4,800,882 A 1/1989 Gianturco
4,816,339 A 3/1989 Tu et al.
4,882,168 A 11/1989 Casey et al.
4,883,699 A * 11/1989 Aniuik et al. 428/36.9
4,886,062 A 12/1989 Wiktor
4,931,287 A 6/1990 Bae et al.
4,941,870 A 7/1990 Okada et al.
4,977,901 A 12/1990 Ofstead
5,019,096 A 5/1991 Fox, Jr. et al.
5,055,518 A * 10/1991 Dupont et al. 525/59
5,079,272 A 1/1992 Allegrezza et al.
5,100,992 A 3/1992 Cohn et al.
5,112,457 A 5/1992 Marchant
5,116,361 A * 5/1992 Kim et al. 623/23.33
5,133,742 A 7/1992 Pinchuk
5,163,952 A 11/1992 Froix
5,165,919 A 11/1992 Sasaki et al.
5,219,980 A 6/1993 Swidler
5,258,020 A 11/1993 Froix
5,272,012 A 12/1993 Opolski
5,284,980 A * 2/1994 Pruckmayr et al. 568/617
5,292,516 A 3/1994 Viegas et al.
5,298,260 A 3/1994 Viegas et al.
5,300,295 A 4/1994 Viegas et al.
5,306,501 A 4/1994 Viegas et al.
5,306,786 A 4/1994 Moens et al.
5,328,471 A 7/1994 Slepian
5,330,768 A 7/1994 Park et al.
5,380,299 A 1/1995 Fearnot et al.
5,417,981 A 5/1995 Endo et al.
5,426,158 A * 6/1995 Mueller et al. 525/455
5,447,724 A 9/1995 Helmus et al.
5,455,040 A 10/1995 Marchant
5,462,990 A 10/1995 Hubbell et al.

(Continued)

FOREIGN PATENT DOCUMENTSDE 42 24 401 1/1994
EP 0 301 856 2/1989

(Continued)

OTHER PUBLICATIONS

IUPAC Compendium of Chemical Terminology 1997.*

(Continued)

Primary Examiner — Juliet Switzer*Assistant Examiner* — Caralynne Helm(74) *Attorney, Agent, or Firm* — Squire Patton Boggs (US) LLP(57) **ABSTRACT**

A coating for implantable medical devices and a method for fabricating thereof are disclosed. The coating includes a mixture of a hydrophobic polymer and a polymeric hydrophilic additive, wherein the hydrophobic polymer and the hydrophilic additive form a physically entangled or interpenetrating system.

17 Claims, 2 Drawing Sheets

(56)

References Cited

U.S. PATENT DOCUMENTS

5,464,650	A	11/1995	Berg et al.	6,015,541	A	1/2000	Greff et al.
5,485,496	A	1/1996	Lee et al.	6,030,634	A	2/2000	Wu et al.
5,516,781	A	5/1996	Morris et al.	6,033,582	A	3/2000	Lee et al.
5,516,881	A	5/1996	Lee et al.	6,034,204	A	3/2000	Mohr et al.
5,563,146	A	10/1996	Morris et al.	6,042,875	A	3/2000	Ding et al.
5,569,463	A	10/1996	Helmus et al.	6,051,576	A	4/2000	Ashton et al.
5,578,073	A	11/1996	Haimovich et al.	6,051,648	A	4/2000	Rhee et al.
5,584,877	A	12/1996	Miyake et al.	6,054,553	A	4/2000	Groth et al.
5,603,894	A	2/1997	Aikus et al.	6,056,993	A	5/2000	Leidner et al.
5,605,696	A	2/1997	Eury et al.	6,060,451	A	5/2000	DiMaio et al.
5,607,467	A	3/1997	Froix	6,060,518	A	5/2000	Kabanov et al.
5,609,629	A	3/1997	Fearnot et al.	6,080,488	A	6/2000	Hostettler et al.
5,610,241	A	3/1997	Lee et al.	6,096,070	A	8/2000	Ragheb et al.
5,616,338	A	4/1997	Fox, Jr. et al.	6,099,562	A	8/2000	Ding et al.
5,624,411	A	4/1997	Tuch	6,110,188	A	8/2000	Narciso, Jr.
5,628,730	A	5/1997	Shapland et al.	6,110,483	A	8/2000	Whitbourne et al.
H001666	H *	7/1997	Stenger-Smith et al.	6,113,629	A	9/2000	Ken
5,644,020	A	7/1997	Timmermann et al.	6,120,491	A	9/2000	Kohn et al.
5,649,977	A	7/1997	Campbell	6,120,536	A	9/2000	Ding et al.
5,658,995	A	8/1997	Kohn et al.	6,120,788	A	9/2000	Barrows
5,667,767	A	9/1997	Greff et al.	6,120,904	A	9/2000	Hostettler et al.
5,670,558	A	9/1997	Onishi et al.	6,121,027	A	9/2000	Clapper et al.
5,674,242	A	10/1997	Phan et al.	6,129,761	A	10/2000	Hubbell
5,679,400	A	10/1997	Tuch	6,136,333	A	10/2000	Cohn et al.
5,700,286	A	12/1997	Tartaglia et al.	6,143,354	A	11/2000	Koulik et al.
5,702,754	A	12/1997	Zhong	6,153,252	A	11/2000	Hossainy et al.
5,711,958	A	1/1998	Cohn et al.	6,156,344	A	12/2000	Kim et al.
5,716,981	A	2/1998	Hunter et al.	6,156,373	A *	12/2000	Zhong et al. 427/2.28
5,721,131	A	2/1998	Rudolph et al.	6,159,978	A	12/2000	Myers et al.
5,723,219	A	3/1998	Kolluri et al.	6,165,212	A	12/2000	Dereume et al.
5,735,897	A	4/1998	Buirge	6,165,509	A	12/2000	Hoffman et al.
5,746,998	A	5/1998	Torchilin et al.	6,172,167	B1	1/2001	Stapert et al.
5,759,205	A	6/1998	Valentini	6,177,523	B1	1/2001	Reich et al.
5,762,944	A *	6/1998	Inoue et al. 424/400	6,180,632	B1	1/2001	Myers et al.
5,776,184	A	7/1998	Tuch	6,203,551	B1	3/2001	Wu
5,783,657	A	7/1998	Pavlin et al.	6,211,249	B1	4/2001	Cohn et al.
5,788,979	A	8/1998	Alt et al.	6,214,901	B1	4/2001	Chudzik et al.
5,800,392	A	9/1998	Racchini	6,224,893	B1 *	5/2001	Langer et al. 424/423
5,820,917	A	10/1998	Tuch	6,231,600	B1	5/2001	Zhong
5,824,048	A	10/1998	Tuch	6,240,616	B1	6/2001	Yan
5,824,049	A	10/1998	Ragheb et al.	6,245,753	B1	6/2001	Byun et al.
5,830,178	A	11/1998	Jones et al.	6,245,760	B1	6/2001	He et al.
5,837,008	A	11/1998	Berg et al.	6,248,129	B1	6/2001	Froix
5,837,313	A	11/1998	Ding et al.	6,251,136	B1	6/2001	Guruwaiya et al.
5,849,859	A	12/1998	Acemoglu	6,254,632	B1	7/2001	Wu et al.
5,851,508	A	12/1998	Greff et al.	6,258,121	B1	7/2001	Yang et al.
5,854,376	A	12/1998	Higashi	6,258,371	B1	7/2001	Koulik et al.
5,858,746	A	1/1999	Hubbell et al.	6,262,034	B1	7/2001	Mathiowitz et al.
5,865,814	A	2/1999	Tuch	6,270,788	B1	8/2001	Koulik et al.
5,869,127	A	2/1999	Zhong	6,270,902	B1 *	8/2001	Tedeschi et al. 428/423.1
5,873,904	A	2/1999	Ragheb et al.	6,273,913	B1	8/2001	Wright et al.
5,876,433	A	3/1999	Lunn	6,277,449	B1	8/2001	Kolluri et al.
5,877,224	A	3/1999	Brocchini et al.	6,283,947	B1	9/2001	Mirzaee
5,879,713	A	3/1999	Roth et al.	6,283,949	B1	9/2001	Roorda
5,902,631	A	5/1999	Wang et al.	6,284,305	B1	9/2001	Ding et al.
5,902,875	A	5/1999	Roby et al.	6,287,628	B1	9/2001	Hossainy et al.
5,905,168	A	5/1999	Dos Santos et al.	6,299,604	B1	10/2001	Ragheb et al.
5,910,564	A	6/1999	Gruning et al.	6,306,176	B1	10/2001	Whitbourne
5,914,387	A	6/1999	Roby et al.	6,331,313	B1	12/2001	Wong et al.
5,919,893	A	7/1999	Roby et al.	6,331,578	B1	12/2001	Turner et al.
5,925,720	A	7/1999	Kataoka et al.	6,335,029	B1	1/2002	Kamath et al.
5,932,299	A	8/1999	Katoot	6,344,035	B1	2/2002	Chudzik et al.
5,955,509	A *	9/1999	Webber et al. 514/772.7	6,346,110	B2	2/2002	Wu
5,958,385	A	9/1999	Tondeur et al.	6,358,556	B1	3/2002	Ding et al.
5,962,138	A	10/1999	Kolluri et al.	6,379,381	B1	4/2002	Hossainy et al.
5,962,516	A	10/1999	Qi et al.	6,384,046	B1	5/2002	Schuler et al.
5,962,620	A	10/1999	Reich et al.	6,387,379	B1	5/2002	Goldberg et al.
5,964,744	A *	10/1999	Balbierz et al. 604/530	6,395,326	B1	5/2002	Castro et al.
5,971,954	A	10/1999	Conway et al.	6,419,692	B1	7/2002	Yang et al.
5,980,928	A	11/1999	Terry	6,451,373	B1	9/2002	Hossainy et al.
5,980,972	A	11/1999	Ding	6,482,834	B2	11/2002	Spada et al.
5,993,972	A	11/1999	Reich et al.	6,494,862	B1	12/2002	Ray et al.
5,997,517	A	12/1999	Whitbourne	6,503,538	B1	1/2003	Chu et al.
6,010,530	A	1/2000	Goicoechea	6,503,556	B2	1/2003	Harish et al.
6,011,125	A	1/2000	Lohmeijer et al.	6,503,954	B1	1/2003	Bhat et al.
				6,506,437	B1	1/2003	Harish et al.
				6,517,858	B1	2/2003	***Haberbosch et al.
				6,524,347	B1	2/2003	Myers et al.
				6,527,801	B1	3/2003	Dutta

(56)

References Cited

U.S. PATENT DOCUMENTS

6,527,863	B1	3/2003	Pacetti et al.	2002/0082679	A1	6/2002	Sirhan et al.
6,528,526	B1	3/2003	Myers et al.	2002/0087123	A1	7/2002	Hossainy et al.
6,530,950	B1	3/2003	Alvarado et al.	2002/0091433	A1	7/2002	Ding et al.
6,530,951	B1	3/2003	Bates et al.	2002/0094440	A1	7/2002	Llanos et al.
6,540,776	B2	4/2003	Sanders Millare et al.	2002/0111590	A1	8/2002	Davila et al.
6,544,223	B1	4/2003	Kokish	2002/0120326	A1	8/2002	Michal
6,544,543	B1	4/2003	Mandrusov et al.	2002/0123801	A1	9/2002	Pacetti et al.
6,544,582	B1	4/2003	Yoe	2002/0133183	A1	9/2002	Lentz et al.
6,555,157	B1	4/2003	Hossainy	2002/0142039	A1	10/2002	Claude
6,558,733	B1	5/2003	Hossainy et al.	2002/0150549	A1	10/2002	Vogt et al.
6,565,659	B1	5/2003	Pacetti et al.	2002/0155212	A1	10/2002	Hossainy
6,572,644	B1	6/2003	Moein	2002/0156188	A1*	10/2002	Anderson et al. 525/107
6,583,272	B1*	6/2003	Bailon 530/397	2002/0165608	A1	11/2002	Llanos et al.
6,585,755	B2	7/2003	Jackson et al.	2002/0176849	A1	11/2002	Slepian
6,585,765	B1	7/2003	Hossainy et al.	2002/0183581	A1	12/2002	Yoe et al.
6,585,926	B1	7/2003	Mirzaee	2002/0188037	A1	12/2002	Chudzik et al.
6,605,154	B1	8/2003	Villareal	2002/0188277	A1	12/2002	Roorda et al.
6,616,765	B1	9/2003	Hossaony et al.	2003/0004141	A1	1/2003	Brown
6,623,448	B2	9/2003	Slater	2003/0028243	A1	2/2003	Bates et al.
6,625,486	B2	9/2003	Lundkvist et al.	2003/0028244	A1	2/2003	Bates et al.
6,645,135	B1	11/2003	Bhat	2003/0031780	A1	2/2003	Chudzik et al.
6,645,195	B1	11/2003	Bhat et al.	2003/0032767	A1	2/2003	Tada et al.
6,656,216	B1	12/2003	Hossainy et al.	2003/0036794	A1	2/2003	Ragheb et al.
6,656,506	B1	12/2003	Wu et al.	2003/0039689	A1	2/2003	Chen et al.
6,660,034	B1	12/2003	Mandrusov et al.	2003/0040712	A1	2/2003	Ray et al.
6,663,662	B2	12/2003	Pacetti et al.	2003/0040790	A1	2/2003	Furst
6,663,880	B1	12/2003	Roorda et al.	2003/0059454	A1*	3/2003	Barry et al. 424/423
6,666,880	B1	12/2003	Chiu et al.	2003/0059520	A1	3/2003	Chen et al.
6,673,154	B1	1/2004	Pacetti et al.	2003/0060877	A1	3/2003	Falotico et al.
6,673,385	B1	1/2004	Ding et al.	2003/0065377	A1	4/2003	Davila et al.
6,689,099	B2	2/2004	Mirzaee	2003/0065382	A1	4/2003	Fischell et al.
6,695,920	B1	2/2004	Pacetti et al.	2003/0072868	A1	4/2003	Harish et al.
6,706,013	B1	3/2004	Bhat et al.	2003/0073961	A1	4/2003	Happ
6,709,514	B1	3/2004	Hossainy	2003/0083646	A1	5/2003	Sirhan et al.
6,712,845	B2	3/2004	Hossainy	2003/0083739	A1	5/2003	Cafferata
6,713,119	B2	3/2004	Hossainy et al.	2003/0097088	A1	5/2003	Pacetti
6,716,444	B1	4/2004	Castro et al.	2003/0097173	A1	5/2003	Dutta
6,723,120	B2	4/2004	Yan	2003/0099712	A1	5/2003	Jayaraman
6,733,768	B2	5/2004	Hossainy et al.	2003/0105518	A1	6/2003	Dutta
6,740,040	B1	5/2004	Mandrusov et al.	2003/0113439	A1	6/2003	Pacetti et al.
6,743,462	B1	6/2004	Pacetti	2003/0144727	A1*	7/2003	Rosenthal et al. 623/1.15
6,749,626	B1	6/2004	Bhat et al.	2003/0150380	A1	8/2003	Yoe
6,753,071	B1	6/2004	Pacetti et al.	2003/0157241	A1	8/2003	Hossainy et al.
6,758,859	B1	7/2004	Dang et al.	2003/0158517	A1	8/2003	Kokish
6,759,054	B2	7/2004	Chen et al.	2003/0190406	A1	10/2003	Hossainy et al.
6,764,505	B1	7/2004	Hossainy et al.	2003/0203991	A1*	10/2003	Schottman et al. 523/334
6,861,503	B2	3/2005	Shalaby	2003/0207020	A1	11/2003	Villareal
7,005,137	B1	2/2006	Hossainy et al.	2003/0208259	A1*	11/2003	Penhasi 623/1.15
7,008,635	B1	3/2006	Coury et al.	2003/0211230	A1	11/2003	Pacetti et al.
7,094,256	B1	8/2006	Shah et al.	2003/0235602	A1*	12/2003	Schwarz 424/424
7,217,426	B1	5/2007	Hossainy	2004/0018296	A1	1/2004	Castro et al.
7,247,313	B2	7/2007	Roorda et al.	2004/0029952	A1	2/2004	Chen et al.
8,435,286	B2*	5/2013	Brister 623/1.42	2004/0047911	A1*	3/2004	Lyu et al. 424/487
8,673,334	B2	3/2014	Pacetti et al.	2004/0047978	A1	3/2004	Hossainy et al.
2001/0007083	A1	7/2001	Roorda	2004/0047980	A1	3/2004	Pacetti et al.
2001/0014717	A1	8/2001	Hossainy et al.	2004/0052858	A1	3/2004	Wu et al.
2001/0018469	A1	8/2001	Chen et al.	2004/0052859	A1	3/2004	Wu et al.
2001/0020011	A1	9/2001	Mathiowitz et al.	2004/0054104	A1	3/2004	Pacetti
2001/0027340	A1	10/2001	Wright et al.	2004/0060508	A1	4/2004	Pacetti et al.
2001/0029351	A1	10/2001	Falotico et al.	2004/0062853	A1	4/2004	Pacetti et al.
2001/0037145	A1	11/2001	Guruwaiya et al.	2004/0063805	A1	4/2004	Pacetti et al.
2001/0051608	A1	12/2001	Mathiowitz et al.	2004/0071861	A1	4/2004	Mandrusov et al.
2002/0005206	A1	1/2002	Falotico et al.	2004/0072922	A1	4/2004	Hossainy et al.
2002/0007213	A1	1/2002	Falotico et al.	2004/0073298	A1	4/2004	Hossainy
2002/0007214	A1	1/2002	Falotico	2004/0086542	A1	5/2004	Hossainy et al.
2002/0007215	A1	1/2002	Falotico et al.	2004/0086550	A1	5/2004	Roorda et al.
2002/0009604	A1	1/2002	Zamora et al.	2004/0086569	A1*	5/2004	Sparer et al. 424/486
2002/0016625	A1	2/2002	Falotico et al.	2004/0096504	A1	5/2004	Michal
2002/0032414	A1	3/2002	Ragheb et al.	2004/0098117	A1	5/2004	Hossainy et al.
2002/0032434	A1	3/2002	Chudzik et al.	2004/0127978	A1*	7/2004	Sparer et al. 623/1.46
2002/0051730	A1	5/2002	Bodnar et al.	2004/0137065	A1*	7/2004	Vogt et al. 424/486
2002/0065551	A1	5/2002	Koole et al.	2005/0191332	A1	9/2005	Hossainy et al.
2002/0065552	A1*	5/2002	Jayaraman et al. 623/1.46				
2002/0071822	A1	6/2002	Uhrich				
2002/0077693	A1	6/2002	Barclay et al.				

FOREIGN PATENT DOCUMENTS

EP	0 396 429	11/1990
EP	0 514 406	11/1992
EP	0 604 022	6/1994
EP	0 623 354	11/1994

(56)

References Cited

FOREIGN PATENT DOCUMENTS

EP	0 665 023	8/1995
EP	0 701 802	3/1996
EP	0 716 836	6/1996
EP	0 809 999	12/1997
EP	0 832 655	4/1998
EP	0 850 651	7/1998
EP	0 879 595	11/1998
EP	0 910 584	4/1999
EP	0 923 953	6/1999
EP	0950386 A2	10/1999
EP	0 953 320	11/1999
EP	0 970 711	1/2000
EP	0 982 041	3/2000
EP	1 023 879	8/2000
EP	1 192957	4/2002
EP	1 273 314	1/2003
FR	2 785 812	5/2000
JP	61-45765	3/1986
JP	2001-190687	7/2001
JP	2002-315823	10/2002
SU	872531	10/1981
SU	876663	10/1981
SU	905228	2/1982
SU	790725	2/1983
SU	1016314	5/1983
SU	811750	9/1983
SU	1293518	2/1987
WO	WO 91/12846	9/1991
WO	WO 94/09760	5/1994
WO	WO 95/10989	4/1995
WO	WO 95/24929	9/1995
WO	WO 96/40174	12/1996
WO	WO 97/10011	3/1997
WO	WO 97/35575	10/1997
WO	WO 97/45105	12/1997
WO	WO 97/46590	12/1997
WO	WO 98/08463	3/1998
WO	WO 98/17331	4/1998
WO	WO 98/32398	7/1998
WO	WO 98/36784	8/1998
WO	WO 98/38687 A1	9/1998
WO	WO 98/58690	12/1998
WO	WO 99/01118	1/1999
WO	WO 99/38546	8/1999
WO	WO 99/63981	12/1999
WO	WO 00/02599	1/2000
WO	WO 00/12147	3/2000
WO	WO 00/18446	4/2000
WO	WO 00/64506	11/2000
WO	WO 01/01890	1/2001
WO	WO 01/15751	3/2001
WO	WO 01/17577	3/2001
WO	WO 01/45763	6/2001
WO	WO 01/49338	7/2001
WO	WO 01/51027	7/2001
WO	WO 01/74414	10/2001
WO	WO 02/03890	1/2002
WO	WO 02/26162	4/2002
WO	WO 02/34311	5/2002
WO	WO 02/056790	7/2002
WO	WO 02/058753	8/2002
WO	WO 02/102283	12/2002
WO	WO 03/000308	1/2003
WO	WO 03/022323	3/2003
WO	WO 03/028780	4/2003
WO	WO 03/037223	5/2003
WO	WO 03/039612	5/2003
WO	WO 03/080147	10/2003
WO	WO 03/082368	10/2003
WO	WO 2004/000383	12/2003
WO	WO 2004/009145	1/2004
WO	WO 2004/010975	2/2004

OTHER PUBLICATIONS

Turner Polymer 1987 26:293-296.*
 Polysciences Inc. reference (1999).*
 Quintana et al. Langmuir 1998 14:1586-1589.*
 U.S. Appl. No. 09/894,293, filed Jun. 27, 2001, Roorda et al.
 U.S. Appl. No. 10/198,912, filed Jul. 19, 2002, Ding et al.
 U.S. Appl. No. 10/177,154, filed Jun. 21, 2002, Hossainy et al.
 U.S. Appl. No. 10/251,111, filed Sep. 19, 2002, Hossainy et al.
 U.S. Appl. No. 10/376,348, filed Feb. 26, 2003, Ding et al.
 U.S. Appl. No. 10/428,691, filed May 1, 2003, Pacetti.
 International Search Report mailed May 10, 2004, for PCT application No. PCT/US2004/009011, filed Mar. 23, 2004, 8 pgs.
 Anonymous, *Cardiologists Draw-Up The Dream Stent*, Clinica 710:15 (Jun. 17, 1996), <http://www.dialogweb.com/cgi/document?req=1061848202959>, printed Aug. 25, 2003 (2 pages).
 Anonymous, *Heparin-coated stents cut complications by 30%*, Clinica 732:17 (Nov. 18, 1996), <http://www.dialogweb.com/cgi/document?req=1061847871753>, printed Aug. 25, 2003 (2 pages).
 Anonymous, *Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent* (Abstract 434009), Res. Disclos. pp. 974-975 (Jun. 2000).
 Anonymous, *Stenting continues to dominate cardiology*, Clinica 720:22 (Sep. 2, 1996), <http://www.dialogweb.com/cgi/document?req=1061848017752>, printed Aug. 25, 2003 (2 pages).
 Aoyagi et al., *Preparation of cross-linked aliphatic polyester and application to thermo-responsive material*, Journal of Controlled Release 32:87-96 (1994).
 Barath et al., *Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury*, JACC 13(2): 252A (Abstract) (Feb. 1989).
 Barbucci et al., *Coating of commercially available materials with a new heparinizable material*, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
 Chung et al., *Inner core segment design for drug delivery control of thermo-responsive polymeric micelles*, Journal of Controlled Release 65:93-103 (2000).
 Dev et al., *Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs*, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
 Dichek et al., *Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells*, Circ. 80(5):1347-1353 (Nov. 1989).
 Eigler et al., *Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin*, JACC, 4A (701-1), Abstract (Feb. 1994).
 Helmus, *Overview of Biomedical Materials*, MRS Bulletin, pp. 33-38 (Sep. 1991).
 Herdeg et al., *Antiproliferative Stent Coatings: Taxol and Related Compounds*, Semin. Intervent. Cardiol. 3:197-199 (1998).
 Huang et al., *Biodegradable Polymers Derived from Aminoacids*, Macromol. Symp. 144, 7-32 (1999).
 Inoue et al., *An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs*, Journal of Controlled Release 51:221-229 (1998).
 Kataoka et al., *Block copolymer micelles as vehicles for drug delivery*, Journal of Controlled Release 24:119-132 (1993).
 Katsarava et al., *Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α -amino acid) α,ω -Alkylene Diesters, and Aliphatic Dicarboxylic Acids*, Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).
 Levy et al., *Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants*, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
 Liu et al., *Drug release characteristics of unimolecular polymeric micelles*, Journal of Controlled Release 68:167-174 (2000).
 Marconi et al., *Covalent bonding of heparin to a vinyl copolymer for biomedical applications*, Biomaterials 18(12):885-890 (1997).
 Matsumaru et al., *Embolic Materials For Endovascular Treatment of Cerebral Lesions*, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).

(56)

References Cited

OTHER PUBLICATIONS

- Miyazaki et al., *Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice*, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
- Miyazawa et al., *Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat*, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
- Nordrehaug et al., *A novel biocompatible coating applied to coronary stents*, European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
- Ohsawa et al., *Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty*, American Heart Journal 136(6):1081-1087 (Dec. 1998).
- Ozaki et al., *New Stent Technologies*, Progress in Cardiovascular Diseases, vol. XXXIX(2):129-140 (Sep./Oct. 1996).
- Pechar et al., *Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin*, Bioconjugate Chemistry 11(2):131-139 (Mar./Apr. 2000).
- Peng et al., *Role of polymers in improving the results of stenting in coronary arteries*, Biomaterials 17:685-694 (1996).
- Saotome, et al., *Novel Enzymatically Degradable Polymers Comprising α -Amino Acid, 1,2-Ethanediol, and Adipic Acid*, Chemistry Letters, pp. 21-24, (1991).
- Shigeno, *Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor*, Chemical Abstract 125:212307 (1996).
- van Beusekom et al., *Coronary stent coatings*, Coronary Artery Disease 5(7):590-596 (Jul. 1994).
- Wilensky et al., *Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries*, Trends Cardiovasc. Med. 3(5):163-170 (1993).
- Yokoyama et al., *Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor*, Journal of Controlled Release 50:79-92 (1998).
- Amendment and Response to OA of a related U.S. Appl. No. 11/903,176, mailed Feb. 3, 2009, 10 pgs.
- Kamath et al., "The Taxus™ drug-eluting stent: A new paradigm in controlled delivery", Advanced Drug Delivery Reviews 58, pp. 412-436 (2006).
- Tesfamariam, "Drug Release Kinetics from Stent Device-Based Delivery Systems", Journal of Cardiovascular Pharmacology 51, pp. 118-125 (2008).
- IUPAC Compendium of Chemical Terminology 2nd Ed. (1997), 4 pgs.
- A Notification of Refusal, issued by JPO on Aug. 17, 2010, in connection with Appl. No. 2006-532338, 3 pgs.
- Translation of a Notification of Refusal, issued by JPO on Aug. 17, 2010, in connection with Appl. No. 2006-532338, 3 pgs.
- "Additive" Definition at <http://www.thefreedictionary.com/additive>, (retrieved from the Internet May 4, 2013).
- Online Conversion (www.onlineconversion.com/energy.htm) (downloaded Dec. 16, 2011).
- Polyethylene Amine (en.wikipedia.org/wiki/Polyethylene_amine) (downloaded Dec. 16, 2011).
- Polyethylenimine (en.wikipedia.org/wiki/Polyethylenimine) (downloaded Dec. 16, 2011).
- Hidalgo et al., The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. *Oncogene* (2000) 19: 6680-6686.
- Luengo et al., Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and position at the FKBP12-FRAP interface. *Chemistry & Biology* (1995) 2:471-481.
- Scheirs, J. (edited) Modern Fluoropolymers (1997) Chapter 31 by Claude Tournut: Thermoplastic Copolymers of Vinylidene Fluoride, John Wiley & Sons, New York, 22 pages.
- Sedrani et al., Chemical modification of rapamycin: the discovery of SDZ RAD. *Transplantation Proc.* (1998) 30:2192-2194.
- The Merck Index, Thirteenth Edition (2001), Merck & Co., Inc., Methyl Acrylate, p. 1075.

* cited by examiner




FIG. 1

FIG. 2





FIG. 3

**FIG. 4**

1

METHODS FOR FORMING STENT COATINGS COMPRISING HYDROPHILIC ADDITIVES

RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 10/431,711 filed 8 May 2003, issued as U.S. Pat. No. 7,279,174 on Oct. 9, 2007, which is incorporated by reference as if fully set forth, including any figures, herein.

FIELD

This invention relates to implantable medical devices such as stents. More particularly, the invention relates to materials that can be used to coat stents.

BACKGROUND

In the field of medical technology, there is frequently a necessity to administer drugs locally. To provide an efficacious concentration to the treatment site, systemic administration of medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. For the treatment of vascular lesions, stents can be modified with a polymeric coating to provide local drug delivery capabilities.

Examples of polymers that can be used to coat stents or other implantable devices include hydrophobic polymers, for example, poly(meth)acrylates, such as poly(n-butyl methacrylate) (PBMA) and copolymers or terpolymers having units derived from n-butyl methacrylate (BMA). PBMA and BMA-based coatings can provide effective control of the rate of release of a drug from a stent. In addition, PBMA and BMA-based polymers are biocompatible, have good adhesion to the underlying stent surface, are easily processable, and possess good physical and mechanical properties such as ability to withstand elongation, compression, and shear that the stent undergoes during crimping onto the catheter, delivery to the lesion site, and expansion.

The properties of PBMA and BMA-based stent coatings can be improved, however. For example, permeability of such coatings can be too low, particularly for drugs having higher molecular weights, leading to potentially insufficient supply of the drug to the diseased site. An ability to better regulate the rate of release through the coatings is desired. The present invention provides such coatings.

BRIEF DESCRIPTION OF DRAWINGS

FIGS. 1-3 are optical micrographs of coatings according to various embodiments of the present invention.

FIG. 4 is a graph illustrating kinetics of in vitro release of a drug through one stent coating of the present invention.

SUMMARY

An implantable medical device comprising a coating is provided, the coating includes a mixture of at least one poly(meth)acrylate and at least one polyalkylene glycol, wherein the macromolecular chains of the poly(meth)acrylate and the polyalkylene glycol form a physically entangled or interpenetrating system. Examples of the poly(meth)acrylate include poly(methyl methacrylate), poly(ethyl methacrylate), poly(n-propyl methacrylate), poly(iso-propyl methacrylate), poly

2

(n-butyl methacrylate), poly(iso-butyl methacrylate), poly(tert-butyl methacrylate), poly(methyl acrylate), poly(ethyl acrylate), poly(n-propyl acrylate), poly(iso-propyl acrylate), poly(n-butyl acrylate), poly(iso-butyl acrylate), and mixtures thereof. Examples of the polyalkylene glycol include poly(ethylene glycol), poly(ethylene oxide), poly(propylene glycol), poly(ethylene oxide-co-propylene oxide), poly(trimethylene glycol), poly(tetramethylene glycol), and mixtures thereof.

An implantable medical device comprising a coating is provided, the coating includes a mixture of at least one hydrophobic polymer and at least one polymeric hydrophilic compound, wherein the macromolecular chains of the hydrophobic polymer and the hydrophilic compound form a physically entangled or interpenetrating system. The hydrophobic polymer can include poly(meth)acrylates, vinyl polymers, polyolefins, halogenated polymers, polymers having urethane groups, polybutyrals, nylon, silicones, polycarbonate, or polysulfone. The polymeric hydrophilic compound can include polyalkylene glycols, hyaluronic acid, chondroitin sulfate, chitosan, glucosaminoglycans, dextran, dextrin, dextran sulfate, cellulose acetate, carboxymethyl cellulose, hydroxyethyl cellulose, cellulose, polypeptides, poly(2-hydroxyethyl methacrylate), polyacrylamide, polyacrylimide, poly(ethylene amine), poly(allyl amine), poly(vinyl pyrrolidone), poly(vinyl alcohol), poly(acrylic acid), poly(methacrylic acid), acrylic acid copolymers, methacrylic acid copolymers, polyvinyl alkyl ethers, non-ionic tetrafunctional block-copolymer surfactants, gelatin, collagen, albumin, chitin, heparin, elastin, fibrin, and mixtures thereof.

A medical article comprising an implantable substrate and a coating is provided, the coating includes a bulk polymer, an additive polymer in less quantity in the coating than the bulk polymer, the additive polymer being entangled or interpenetrated with the bulk polymer, and a drug.

A method for fabricating a coating for an implantable medical device is provided, the method comprises forming a coating on the device, the coating including a mixture of at least one hydrophobic polymer and at least one polymeric hydrophilic compound, wherein the macromolecular chains of the hydrophobic polymer and the hydrophilic compound form a physically entangled or intertwined system.

DETAILED DESCRIPTION

A coating for an implantable medical device, such as a stent, can include an optional primer layer, a drug-polymer layer, and an optional topcoat layer. The drug-polymer layer can be applied directly onto at least a part of the stent surface to serve as a reservoir for an active agent or a drug which is incorporated into the drug-polymer layer. An optional primer layer can be applied between the stent and the drug-polymer layer to improve the adhesion of the drug-polymer layer to the stent. An optional topcoat layer can be applied over at least a part of the drug-polymer layer to reduce the rate of release of the drug from the reservoir.

The topcoat layer, if used, is the outermost layer of the stent coating. If the topcoat layer is not used, the drug-polymer layer is the outermost layer of the stent coating. The drug-polymer and/or topcoat layer of the stent coating can include at least one hydrophobic polymer. To regulate a rate of release of the drug from the drug-polymer layer the hydrophobic polymer(s) can be physically mixed or blended with at least one polymeric hydrophilic additive to form a polymer system where the macromolecular chains of the hydrophobic polymer and the hydrophilic additive are physically entangled,

miscible, and/or interpenetrating. This polymer system can be, in one embodiment, the outermost region or layer of the coating.

Hereinafter, the hydrophobic polymer is also referred to as “polymer,” and polymeric hydrophilic additive is also referred to as “additive.” The term “physically entangled” is defined hereinafter as a polymer/additive composition in which neither the polymer nor the additive forms a separate phase domain having a size larger than about 100 nanometers, such as the size larger than about 200 nanometers, for example, larger than about 300 nanometers. The size of the domain is determined by the largest linear dimension of the domain particle, e.g., by the diameter of a particle in case the domain particles are spheres. The definition of “physically entangled” also includes a condition that once the polymer and the additive have become physically entangled, they do not disentangle but remain physically entangled for the duration of the service of the coating or until the drug has been released from the coating.

The hydrophobic polymer and the hydrophobic additive are defined hereinafter as “miscible” if the thermogram of the polymer/additive mixture shows substantially no thermal transitions attributable to either the essentially pure polymer or the essentially pure additive. The thermogram can be obtained by a standard method of thermal analysis known to those having ordinary skill in the art, for example, by the method of differential scanning calorimetry.

The term “interpenetrating” is defined as the polymer/additive system where the polymer and the additive form an interpenetrating polymer network (IPN). The definition of the IPN used by the International Union of Pure and Applied Chemistry (IUPAC) is adopted herein. The IUPAC describes the IPN as a polymer comprising two or more networks which are at least partially interlaced on a molecular scale, to form both chemical and physical bonds between the networks. The networks of an IPN cannot be separated unless chemical bonds are broken. In other words, an IPN structure represents two or more polymer networks that are partially chemically cross-linked and partially physically entangled.

To define the terms “hydrophobic” and “hydrophilic” for the purposes of the present invention, one of the two criteria can be used. According to one criterion, a component in the polymer/additive system (i.e., the polymer or the additive) can be classified by the value of the component’s equilibrium water adsorption. Whichever component in the polymer/additive system has the greater value of the equilibrium water adsorption at room temperature is considered hydrophilic and the other component is considered hydrophobic. If more than two components are used in the polymer/additive system, then each can be ranked in order of its equilibrium water adsorption value. In one embodiment, the polymer is considered hydrophobic if it has an equilibrium water adsorption less than 10 mass % at room temperature, and the additive is considered hydrophilic if it has an equilibrium water adsorption at room temperature of 10 mass % or greater.

According to another criterion, a component in the polymer/additive system can be classified by the value of the component’s Hildebrand solubility parameter δ . The term “Hildebrand solubility parameter” refers to a parameter measuring the cohesion of a substance and is determined as follows:

$$\delta = (\Delta E/V)^{1/2};$$

where δ is the solubility parameter, $(\text{cal}/\text{cm}^3)^{1/2}$;
 ΔE is the energy of vaporization, cal/mole ; and
 V is the molar volume, cm^3/mole .

Whichever component in the polymer/additive system has lower δ value compared to the δ value of the other component in the blend is designated as a hydrophobic component, and the other component with higher δ value is designated as hydrophilic. If more than two components are used in the blend, then each can be ranked in order of its δ value. In one exemplary embodiment, the δ value defining the boundary between the hydrophobic and hydrophilic components of the polymer/additive system can be about $10.7 (\text{cal}/\text{cm}^3)^{1/2}$.

Hydrophobic substances typically have a low δ value. In one embodiment, a component in the polymer/additive system that is “hydrophobic” can have a Hildebrand solubility parameter lower than about $10.7 (\text{cal}/\text{cm}^3)^{1/2}$. A component in the polymer/additive system that is “hydrophilic” can have a solubility parameter greater than about $10.7 (\text{cal}/\text{cm}^3)^{1/2}$.

To make the polymer/additive mixture, the polymer can be blended with the additive and the blend can be dissolved in a solvent or in a system comprising a mixture of solvents. The term “dissolved” means that the polymer/additive blend, when combined with a suitable solvent or a mixture of solvents, is capable of forming a system which can be applied on a stent by a common technique, such as spraying or dipping. The solvent or a mixture of solvents can be selected by those having ordinary skill in the art depending, among other factors, on the nature of the polymer and the additive.

The polymer/additive solution can be then applied on the stent by a commonly known technique known to those having ordinary skill in the art, for example, by spraying or dipping, followed by drying, for example, by baking. The polymer/additive solution can be used to form the topcoat layer and/or the drug-polymer layer of the stent coating.

The combined mass concentration of the polymer and the additive in the polymer/additive solution can be between about 1% and about 10%, for example, about 2%. A ratio between the hydrophobic polymer and the polymeric hydrophilic additive in the polymer/additive solution can be between about 99:1 and about 9:1, such as between about 74:1 and about 14:1, more narrowly between about 49:1 and about 19:1. For example, for a polymer/additive solution containing about 2 mass % of the hydrophobic polymer, the concentration of the polymeric hydrophilic additive can be between about 0.04 and about 0.1 mass % of the total mass of the solution.

The polymer/additive solution can be prepared by various alternative methods. For example, the hydrophobic polymer and the polymeric hydrophilic additive can be dissolved separately to obtain a hydrophobic polymer solution and a polymeric hydrophilic additive solution, followed by combining the two solutions to form the polymer/additive solution. Alternatively, the hydrophobic polymer can be dissolved first to form the hydrophobic polymer solution, followed by adding the polymeric hydrophilic additive to the hydrophobic polymer solution to form the polymer/additive solution. As another alternative, the additive can be dissolved first to form the additive solution followed by adding the polymer to form the polymer/additive solution.

Examples of hydrophobic polymers include poly(meth)acrylates. The term “poly(meth)acrylates” refers to both polymethacrylates and polyacrylates. Examples of poly(meth)acrylates that can be used include homo- and copolymers of butyl methacrylate, for example PBMA, poly(vinylidene fluoride-co butyl methacrylate), or poly(methyl methacrylate-co-butyl methacrylate). Representative examples of other hydrophobic polymers that can be used in practice of the present invention include the following polymers and mixtures thereof:

5

- (a) poly(meth)acrylates other than PBMA or BMA-based polymethacrylates, such as poly(methyl methacrylate), poly(ethyl methacrylate), poly(n-propyl methacrylate), poly(iso-propyl methacrylate), poly(tert-butyl methacrylate), poly(methyl acrylate), poly(ethyl acrylate), poly(n-propyl acrylate), poly(iso-propyl acrylate), poly(n-butyl acrylate), and poly(iso-butyl acrylate);
- (b) vinyl polymers such as poly(ethylene-co-vinyl alcohol), for example, poly(ethylene-co-vinyl alcohol) having a molar content of ethylene-derived units of at least 44%, poly(ethylene-co-vinyl acetate), poly(vinyl acetate), polystyrene, poly(styrene-co-iso-butylene), poly(styrene-co-ethylene-co-butylene-co-styrene) terpolymers, and poly(styrene-co-butadiene-co-styrene) terpolymers;
- (c) polyolefins, for example, atactic polypropylene;
- (d) halogenated (e.g., fluorinated or chlorinated) polymers such as poly(vinyl fluoride), poly(vinylidene fluoride), polyhexafluoropropene, poly(hexafluoropropene-co-vinylidene fluoride), poly(ethylene-co-hexafluoropropene), various grades of amorphous TEFLON (including polytetrafluoroethylene) available from E.I. Du Pont de Nemours & Co., poly(vinyl chloride), and poly(vinylidene chloride);
- (e) polymers having urethane groups, such as polyether urethanes, polyester urethanes, polyurethaneureas, polycarbonate urethanes, and silicone urethanes; and
- (f) polybutyral, nylon, silicones, polycarbonate, and polysulfone.

Representative examples of polymeric hydrophilic additives that can be used in practice of the present invention include hyaluronic acid, chondroitin sulfate, chitosan, glucosaminoglycans, dextran, dextrin, dextran sulfate, cellulose acetate, carboxymethyl cellulose, hydroxyethyl cellulose, cellulosics, poly(ethylene glycol)(PEG), poly(ethylene oxide), poly(propylene glycol), PLURONIC®, TETRONIC®, poly(trimethylene glycol), poly(tetramethylene glycol), polypeptides, poly(2-hydroxyethyl methacrylate), polyacrylamide, polyacrylimide, poly(ethylene amine), poly(allyl amine), poly(vinyl pyrrolidone), poly(vinyl alcohol), poly(acrylic acid), poly(methacrylic acid), acrylic acid copolymers, methacrylic acid copolymers, polyvinyl alkyl ethers such as poly(vinylmethyl ether) or poly(vinylethyl ether); gelatin, collagen, albumin, chitin, heparin, elastin, fibrin and mixtures thereof. PLURONIC® is a trade name of a poly(ethylene oxide-co-propylene oxide). TETRONIC® is a trade name of a family of non-ionic tetrafunctional block-copolymer surfactants. PLURONIC® and TETRONIC® are available from BASF Corp. of Parsippany, N.J.

To achieve the physical entanglement of the hydrophobic polymer and polymeric hydrophilic additive, at least one polymer and at least one additive can be blended together in a common solvent system that includes at least one very volatile solvent, followed by applying the solution onto a stent, for example, by spraying. As used herein, "very volatile solvent" means a solvent that has a vapor pressure greater than 30 Torr at ambient temperature. Examples of very volatile solvent include acetone and methyl ethyl ketone. Alternatively, to physically entangle the hydrophobic polymer and polymeric hydrophilic additive, the polymer and the additive can be blended in the melt, and then applied to the stent from the melt, for example by curtain coating.

One way of forming an interpenetrating system of the hydrophobic polymer and polymeric hydrophilic additive is by blending the polymer and the additive in a solvent, or solvent blend, in which both components are soluble. The

6

solution can be applied onto a stent, for example, by spraying, followed by the removal of the solvent by drying. For the polymer and the additive which are capable of forming an interpenetrating system, the polymers and the additive are expected to interpenetrate while still in solution, and to remain interpenetrated upon solvent removal.

Alternatively, to form an interpenetrating system of the hydrophobic polymer and polymeric hydrophilic additive, the polymer and additive, which can be polymerized according to two different mechanisms, can be selected. For example, the hydrophobic component can be a carbonate urethane that is polymerized by condensation reactions between isocyanate and hydroxyl groups, while the hydrophilic additive can be poly(2-hydroxyethyl methacrylate) that polymerizes by a free radical mechanism. The monomers may be dissolved in a common solvent system, applied to the stent, and then polymerized directly on the stent.

As another alternative way of forming an interpenetrating system of the hydrophobic polymer and polymeric hydrophilic additive, a high molecular weight polymer and additive can be selected, each component having reactive or associative groups that can interact with the reactive or associative groups of the other component. For example, such hydrophilic additive as hydroxy terminated PEG can be blended with a high molecular weight, hydrophobic polyurethane with active isocyanate groups along the backbone. The additive and the polymer can be blended in solution, sprayed onto a stent, followed by curing. Although sometimes the two components may be not miscible, the covalent bonds between them can still prevent phase separation.

To facilitate the formation of an entangled and/or interpenetrating hydrophobic polymer-polymeric hydrophilic additive system, the polymer and the additive can be selected in such a way that the chain lengths of the polymer and the additive, as determined by degree of polymerization, are such as to promote the entanglement and/or interpenetration of the macromolecules of the polymer and the additive. The term "degree of polymerization" refers to a number of repeating monomeric units in a single macromolecule. The chain lengths that promote the formation of an entangled and/or interpenetrating network can be such that the contour length of the hydrophilic additive lies in the range of between about 10% and about 100% of the contour length of the hydrophobic polymer, for example, between 50% and 100%, such as 80%. The term "contour length" refers to the combined length of all bonds along the main chain (the backbone) of a macromolecule. The contour length can be approximated as the degree of polymerization multiplied by the number of bonds in the repeat unit times the average bond length, where the degree of polymerization may be calculated as the number average molecular weight divided by the repeat unit molecular weight. An average bond length of about 1.4 Å can be used for the computation. The following example can be used to illustrate how the molecular weights of the polymer and the additive can be chosen to achieve a proper ratio between the contour lengths of the polymer and the additive.

PBMA with a number-averaged molecular weight (M_n) of about 200,000, has a degree of polymerization of 1,408 and has 2 bonds in the polymer backbone per repeat unit. Thus, if 1.4 Å is used as the bond length, a contour length of a PBMA macromolecule is about 3,940 Å. Suitable hydrophilic additive to achieve entanglement can be PEG having contour lengths between about 394 Å and about 3,940 Å. PEG has 3 bonds per repeat unit, so for PEG having contour lengths between about 394 Å and about 3,940 Å, corresponding

degree of polymerization is approximately between 131 and 1,313, and the corresponding M_n is between about 5,780 and about 57,800.

Generally, M_n of the hydrophobic polymer can be between about 50,000 and 1000,000 Daltons, for example, about 100,000 Daltons. The molecular weight of the hydrophilic additive can be between about 5,000 and about 100,000 Daltons, for example, about 40,000 Daltons. If PBMA is used as the hydrophobic polymer, the molecular weight of PBMA can be between about 100,000 and about 300,000 Daltons, for example, about 200,000 Daltons. If PEG is used as the hydrophilic additive being mixed with PBMA, the molecular weight of PEG can be between about 10,000 and about 60,000 Daltons, for example, about 20,000 Daltons.

The embodiments of the present invention are described in connection with a stent, e.g., balloon expandable or self-expandable stents; however, other implantable medical devices can also be coated. Examples of such implantable devices include stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE® and ENDOTAK, ® available from Guidant Corp. of Santa Clara, Calif.). The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY®), stainless steel (316L), "MP35N," "MP20N," ELASTINITE® (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. "MP35N" and "MP20N" are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co. of Jenkintown, Pa. "MP35N" consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. "MP20N" consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention. The device itself can be made in whole or in part from the disclosed polymeric blends.

For the drug-polymer layer, the coating can include an active agent or a drug. The drug can include any substance capable of exerting a therapeutic or prophylactic effect for a patient. The drug may include small molecule drugs, peptides, proteins, oligonucleotides, and the like. The drug could be designed, for example, to inhibit the activity of vascular smooth muscle cells. It can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit restenosis.

Examples of drugs include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich of Milwaukee, Wisconsin, or COSMEGEN® available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I₁, actinomycin X₁, and actinomycin C₁. The active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimetabolic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimetotics include paclitaxel (e.g. TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. TAXOTERE®, from Aventis S.A., Frankfurt, Germany), methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. ADRIAMYCIN® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. MUTAMYCIN® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin,

vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as ANGIOMAX™ (bivalirudin, Biogen, Inc., Cambridge, Mass.). Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. CAPOTEN® and CAPOZIDE® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. PRINIVIL® and PRINZIDE® from Merck & Co., Inc., Whitehouse Station, NJ); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name MEVACOR® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and donors of nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, tacrolimus, dexamethasone, and rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the name of everolimus, available from Novartis), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

The molecular weight of the drug can influence the choice of the molecular weights of the polymer and the additive, as well as the ratios between the polymer and the additive, since the release rates of the drugs having higher molecular weights are expected to be slower compared with the release rates of the drugs with lower molecular weights. To illustrate, when the PBMA/PEG topcoat system is used in conjunction with everolimus (having molecular weight 958 Daltons), M_n of PBMA can be between about 90,000 Daltons and about 300,000 Daltons, for example, about 190,000 Daltons and M_n of PEG can be between about 6,000 Daltons and about 20,000 Daltons, for example, about 18,000 Daltons, and the mass ratio between PBMA and PEG can be between about 49:1 and about 9:1, for example, about 20:1. At the same time, in the case of estradiol (having molecular weight of 272), M_n of PBMA can be between about 150,000 Daltons and about 900,000 Daltons, for example, about 300,000 Daltons and M_n of PEG can be between about 10,000 Daltons and about 50,000 Daltons, for example, about 30,000 Daltons, and the mass ratio between PBMA and PEG can be between about 99:1 and about 25:1, for example about 49:1.

Embodiments of the present invention are further illustrated by the following examples.

EXAMPLE 1

A first polymer solution was prepared, the solution containing:

- about 5 mass % of poly(n-butyl methacrylate) (PBMA) having M_n of about 154,000; and
- the balance, solvent mixture of acetone and cyclohexanone, the mixture having a mass ratio between acetone and cyclohexanone of about 4:1.

9

A second polymer solution was prepared, the solution containing:

- (a) about 5 mass % of poly(ethylene glycol) (PEG) having M_n of about 18,000; and
- (b) the balance, solvent mixture of acetone and cyclohexanone, the mixture having a mass ratio between acetone and cyclohexanone of about 4:1.

The first polymer solution was combined with the second polymer solution to prepare a PBMA/PEG solution. The amount of the first and second polymer solutions were selected to obtain the PBMA/PEG solution having a mass ratio between PBMA and PEG of about 49:1.

The PBMA/PEG solution was cast on a glass slide, and the solvent was removed by drying at room temperature followed by baking at about 80° C. for about 1 hour. As a result, an adhered polymer film was formed on the glass slide. An optical micrograph of the dry PBMA/PEG film was taken in transmitted polarized light, as shown by FIG. 1. Under such light, amorphous polymers appear dark and crystalline polymers appear bright. As seen from FIG. 1, the PBMA/PEG system appears uniformly dark showing good miscibility of PBMA and PEG. FIG. 1 does not show that PEG forms a separate phase.

EXAMPLE 2

A PBMA/PEG solution was prepared as described in Example 1, except the mass ratio between PBMA and PEG in the PBMA/PEG solution was about 19:1. A polymer film was formed on a glass slide out of the PBMA/PEG solution as described in Example 1. An optical micrograph of the dry PBMA/PEG film was taken as described in Example 1. The micrograph is shown by FIG. 2. As seen from FIG. 2, the PBMA/PEG system appears mostly uniform, with some amount of the crystalline phase formed by PEG represented by bright spots on the micrograph.

EXAMPLE 3

A PBMA/PEG solution was prepared as described in Example 1, except the mass ratio between PBMA and PEG in the PBMA/PEG solution was about 10:1. A polymer film was formed on a glass slide out of the PBMA/PEG solution as described in Example 1. An optical micrograph of the dry PBMA/PEG film was taken as described in Example 1. The micrograph is shown by FIG. 3. As seen from FIG. 3, the PBMA/PEG system includes visible crystalline areas. Compared with the film described in Example 2, the film shown by FIG. 3 included more substantial amount of the crystalline phase formed by PEG.

EXAMPLE 4

A first composition was prepared by mixing the following components:

- (a) between about 1.0 mass % and about 15 mass %, for example, about 2.0 mass % of poly(ethylene-co-vinyl alcohol) (EVAL); and
- (b) the balance, DMAC solvent.

The first composition was applied onto the surface of a bare 18 mm VISION stent (available from Guidant Corp.) by spraying and dried to form a primer layer. A spray coater was used, having a 0.014 fan nozzle maintained at about 60° C. with a feed pressure of about 0.2 atm (about 3 psi) and an atomization pressure of about 1.3 atm (about 20 psi). About

10

70 µg of the wet coating was applied. The wet coating was baked at about 140° C. for about 2 hours, yielding a dry primer layer.

A second composition was prepared by mixing the following components:

- (a) about 2.0 mass % of EVAL;
- (b) about 1.6 mass % of everolimus; and
- (c) the balance, DMAC solvent.

The second composition was applied onto the dried primer layer to form a drug-polymer layer, using the same spraying technique and equipment used for applying the primer layer. About 300 µg of the wet coating was applied, followed by drying, e.g., by baking as described above. The dry drug-polymer layer contained about 130 µg of everolimus.

A third composition was prepared by mixing the following components:

- (a) about 2 mass % of PBMA having M_n of about 154,000; and
- (b) about 0.1 mass % of PEG having M_n of about 18,000; and
- (c) the balance, a 1:1 by mass mixture of solvents, acetone and cyclohexanone.

The third composition was applied onto the dried drug-polymer layer, to form a topcoat layer, using the same spraying technique and equipment used for applying the primer and the drug-polymer layers. About 200 µg of the wet coating was applied, followed by drying, e.g., by baking as described above. The final amount of the dried topcoat was about 50 µg.

The kinetics of release of everolimus in vitro was studied chromatographically (HPLC). To study the kinetics, three stents were coated as described above in this Example. The results of this study are illustrated by the chart shown by FIG. 4. The amount of EVEROLIMUS released from a stent coating having the PBMA-PEG topcoat was measured (curve 1). The average of the data obtained from the three stents was used to plot curve 1. As a control, two identical control stents were used, except the topcoat included only pure PBMA instead of PBMA-PEG. The control curve 2 was plotted using the average of the data obtained from the two control stents. As seen from FIG. 4, the rate of release of everolimus through the PBMA-PEG topcoat is about twice the rate of release through the PBMA topcoat.

EXAMPLE 5

A primer and drug-polymer layers can be formed on a stent as described in Example 4, but instead of everolimus, rapamycin can be used. A topcoat composition can then be prepared by mixing the following components:

- (a) about 2 mass % of PBMA having M_n of about 154,000; and
- (b) about 0.05 mass % of PEG having M_n of about 18,000;
- (c) about 0.05 mass % of poly(propylene glycol) (PPG) having M_n of about 40,000; and
- (c) the balance, a 1:1 by mass mixture of solvents, acetone and cyclohexanone.

If desired, poly(tetramethylene glycol) (PTMG) can be used in the topcoat composition instead of PPG. The M_n of PTMG can also be about 40,000. A PPG/PTMG blend having any ratio between PPG and PTMG can also be optionally used instead of PPG. In this example, in the topcoat composition the mass ratio between PEG and PPG is 1:1. If desired, the amount of PPG or PTMG, or a mixture thereof can be up to about twice amount of PEG. Optionally, all of the PEG in the topcoat composition can be replaced with PPG or PTMG, or with a mixture thereof.

11

The topcoat composition can be applied onto the dried drug-polymer layer, to form a topcoat layer, using the same spraying technique and equipment used for applying the primer and the drug-polymer layers. About 200 µg of the wet coating can be applied, followed by drying, e.g., by baking as described above. The final amount of the dried topcoat can be about 50 µg.

EXAMPLE 6

A primer and drug-polymer layers can be formed on a stent as described in Example 4. A topcoat composition can then be prepared by mixing the following components:

- (a) between about 1.0 mass % and about 15 mass %, for example, about 1.9 mass % of poly(hexafluoropropene-co-vinylidene fluoride) (PHFP-VDF) having M_n about 125,000.
- (b) between about 0.04 mass % and about 0.8 mass %, for example, about 0.1 mass % of F127 PLURONIC copolymer; and
- (c) the balance, a mixture of solvents, the solvent mixture including acetone and cyclohexanone in a mass ratio of about 1:1.

F127 PLURONIC is a difunctional poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer terminating in primary hydroxyl groups. F127 PLURONIC has M_n of about 12,600.

The topcoat composition can be applied onto the dried drug-polymer layer, to form a topcoat layer, using the same spraying technique and equipment used for applying the primer and the drug-polymer layers. About 200 µg of the wet coating can be applied, followed by drying, e.g., by baking as described above. The final amount of the dried topcoat can be about 50 µg.

While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

What is claimed is:

1. A method of fabricating a coating for an implantable medical device comprising:

- providing an implantable medical device;
- preparing a solution comprising at least one hydrophobic polymer comprising a macromolecular chain, at least one hydrophilic polymer comprising a macromolecular chain, and either a solvent or a blend of solvents;
- applying the solution to the implantable medical device;

and
removing the solvent or the blend of solvents;
wherein a physically entangled or intertwined system is formed of the
macromolecular chains of the hydrophobic polymer and the hydrophilic polymer; and

wherein at least one hydrophobic polymer is selected from the group consisting of polyurethaneureas with a Hildebrand solubility parameter (δ) of less than 10.7 (cal/cm³)^{1/2}.

2. The method of claim 1, wherein the coating further comprises a drug.

3. The method of claim 1, wherein the hydrophilic polymer is selected from the group consisting of polyalkylene glycols, hyaluronic acid, chondroitin sulfate, chitosan, glucosaminoglycans, dextran, dextrin, dextran sulfate, cellulose acetate, carboxymethyl cellulose, hydroxyethyl cellulose, cellulotics,

12

polypeptides, poly(2-hydroxyethyl methacrylate), polyacrylamide, polyacrylimide, poly(ethylene amine), poly(allyl amine), poly(vinyl pyrrolidone), poly(vinyl alcohol), poly(acrylic acid), poly(methacrylic acid), acrylic acid copolymers, methacrylic acid copolymers, polyvinyl alkyl ethers, non-ionic tetrafunctional block-copolymer surfactants, gelatin, collagen, albumin, chitin, heparin, elastin, fibrin, and mixtures thereof.

4. The method of claim 3, wherein the polyalkylene glycols are selected from the group consisting of poly(ethylene glycol), poly(ethylene oxide), poly(propylene glycol), poly(ethylene oxide-co-propylene oxide), poly(trimethylene glycol), poly(tetramethylene glycol), and mixtures thereof.

5. The method of claim 1, wherein the solution further comprises everolimus, 40-O-tetrazole-rapamycin, or a combination thereof.

6. The method of claim 1, wherein a mass ratio between the hydrophobic polymer and the hydrophilic polymer is between about 49:1 and about 19:1.

7. A method of fabricating a coating for an implantable medical device, comprising forming a coating on the device, the coating comprising a mixture of at least one hydrophobic polymer and at least one hydrophilic polymer;

wherein the macromolecular chains of the hydrophobic polymer and the hydrophilic polymer form a physically entangled or intertwined system;

and

wherein the hydrophobic polymer comprises poly(meth)acrylates

selected from the group consisting of poly(iso-propyl methacrylate), poly(iso-propyl acrylate), and mixtures thereof.

8. The method of claim 7, wherein the implantable medical device is a stent.

9. The method of claim 7, wherein the contour length of the hydrophilic polymer is in the range of about 10% to about 100% of the contour length of the hydrophobic polymer.

10. The method of claim 7, wherein the hydrophilic polymer is selected from a group consisting of polyalkylene glycols, hyaluronic acid, chondroitin sulfate, chitosan, glucosaminoglycans, dextran, dextrin, dextran sulfate, cellulose acetate, carboxymethyl cellulose, hydroxyethyl cellulose, cellulotics, polypeptides, poly(2-hydroxyethyl methacrylate), polyacrylamide, polyacrylimide, poly(ethylene amine), poly(allyl amine), poly(vinyl pyrrolidone), poly(vinyl alcohol), poly(acrylic acid), poly(methacrylic acid), acrylic acid copolymers, methacrylic acid copolymers, polyvinyl alkyl ethers, non-ionic tetrafunctional block-copolymer surfactants, gelatin, collagen, albumin, chitin, heparin, elastin, fibrin, and mixtures thereof.

11. The method of claim 10, wherein the polyalkylene glycols are selected from a group consisting of poly(ethylene glycol), poly(ethylene oxide), poly(propylene glycol), poly(ethylene oxide-co-propylene oxide), poly(trimethylene glycol), poly(tetramethylene glycol), and mixtures thereof.

12. The method of claim 7, wherein a mass ratio between the hydrophobic polymer and the hydrophilic polymer additive is between about 99:1 and about 9:1.

13. The method of claim 12, wherein the mass ratio between the hydrophobic polymer and the hydrophilic polymer is between about 74:1 and about 14:1.

14. The method of claim 13, wherein the mass ratio between the hydrophobic polymer and the hydrophilic polymer is between about 49:1 and about 19:1.

15. The method of claim 7, wherein the coating further comprises a drug.

16. The device of claim 15, wherein the drug is selected from a group consisting of rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, and combinations thereof. 5

17. The method of claim 7, wherein forming the coating on the device comprises:

preparing a solution by executing an operation comprising dissolving the at least one hydrophobic polymer comprising the macromolecular chain and the at least one 10 hydrophilic polymer comprising the macromolecular chain in a solvent or a blend of solvents;

applying the solution to the implantable medical device; and

removing the solvent or the blend of solvents; 15

wherein the solvent or the blend of solvents has a vapor pressure of 30 Torr or higher at the temperature of coating formation.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 9,175,162 B2
APPLICATION NO. : 11/903011
DATED : November 3, 2015
INVENTOR(S) : Pacetti et al.

Page 1 of 1


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page:

The first or sole Notice should read --

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b)
by 3 days.

Signed and Sealed this
Sixth Day of September, 2016

A handwritten signature in black ink, reading "Michelle K. Lee". The signature is fluid and cursive, with the first letters of each name being capitalized and prominent.

Michelle K. Lee
Director of the United States Patent and Trademark Office